Vanda Pharmaceuticals Future Growth
Future criteria checks 1/6
Vanda Pharmaceuticals's revenue is forecast to decline at 4.3% per annum while its annual earnings are expected to grow at 2.4% per year. EPS is expected to decline by 0.8% per annum.
Key information
2.4%
Earnings growth rate
-0.8%
EPS growth rate
Biotechs earnings growth | 27.9% |
Revenue growth rate | -4.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 27 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 152 | 9 | 298 | 299 | 1 |
12/31/2025 | 232 | -19 | 254 | 255 | 1 |
12/31/2024 | 195 | -4 | 190 | 191 | 1 |
12/31/2023 | 193 | 3 | -88 | 13 | N/A |
9/30/2023 | 212 | 12 | 26 | 26 | N/A |
6/30/2023 | 238 | 15 | 40 | 41 | N/A |
3/31/2023 | 257 | 16 | 59 | 60 | N/A |
12/31/2022 | 254 | 6 | 31 | 32 | N/A |
9/30/2022 | 258 | 6 | 49 | 49 | N/A |
6/30/2022 | 263 | 11 | 45 | 46 | N/A |
3/31/2022 | 266 | 18 | 59 | 59 | N/A |
12/31/2021 | 269 | 33 | 64 | 64 | N/A |
9/30/2021 | 268 | 34 | 56 | 57 | N/A |
6/30/2021 | 259 | 32 | 55 | 57 | N/A |
3/31/2021 | 253 | 32 | 60 | 62 | N/A |
12/31/2020 | 248 | 23 | 50 | 52 | N/A |
9/30/2020 | 241 | 19 | 41 | 42 | N/A |
6/30/2020 | 241 | 114 | 38 | 39 | N/A |
3/31/2020 | 237 | 117 | 34 | 35 | N/A |
12/31/2019 | 227 | 116 | 45 | 46 | N/A |
9/30/2019 | 219 | 122 | 50 | 51 | N/A |
6/30/2019 | 209 | 28 | 53 | 54 | N/A |
3/31/2019 | 197 | 22 | 12 | 38 | N/A |
12/31/2018 | 193 | 25 | 5 | 30 | N/A |
9/30/2018 | 184 | 13 | -7 | 18 | N/A |
6/30/2018 | 177 | 1 | -14 | 12 | N/A |
3/31/2018 | 171 | -5 | 4 | 5 | N/A |
12/31/2017 | 165 | -16 | -4 | -2 | N/A |
9/30/2017 | 159 | -14 | N/A | -7 | N/A |
6/30/2017 | 156 | -10 | N/A | -8 | N/A |
3/31/2017 | 150 | -13 | N/A | -9 | N/A |
12/31/2016 | 146 | -18 | N/A | -8 | N/A |
9/30/2016 | 140 | -32 | N/A | -7 | N/A |
6/30/2016 | 129 | -41 | N/A | -13 | N/A |
3/31/2016 | 121 | -42 | N/A | 2 | N/A |
12/31/2015 | 110 | -40 | N/A | 12 | N/A |
9/30/2015 | 93 | 45 | N/A | -1 | N/A |
6/30/2015 | 80 | 53 | N/A | -3 | N/A |
3/31/2015 | 63 | 36 | N/A | -52 | N/A |
12/31/2014 | 50 | 20 | N/A | -82 | N/A |
9/30/2014 | 44 | -57 | N/A | -80 | N/A |
6/30/2014 | 37 | -61 | N/A | -83 | N/A |
3/31/2014 | 35 | -43 | N/A | -54 | N/A |
12/31/2013 | 34 | -21 | N/A | -40 | N/A |
9/30/2013 | 33 | -20 | N/A | -41 | N/A |
6/30/2013 | 33 | -20 | N/A | -41 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0LKB's forecast earnings growth (2.4% per year) is above the savings rate (1.8%).
Earnings vs Market: 0LKB's earnings (2.4% per year) are forecast to grow slower than the UK market (12.4% per year).
High Growth Earnings: 0LKB's earnings are forecast to grow, but not significantly.
Revenue vs Market: 0LKB's revenue is expected to decline over the next 3 years (-4.3% per year).
High Growth Revenue: 0LKB's revenue is forecast to decline over the next 3 years (-4.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0LKB's Return on Equity is forecast to be high in 3 years time